Imago BioSciences Investor Relations Material
Latest events
Q3 2022
9 Nov, 2022
Q2 2022
12 Aug, 2022
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Imago BioSciences Inc
Access all reports
Imago BioSciences, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme used in the production of blood cells in the bone marrow. We are conducting clinical trials for bomedemstat which is being developed as a treatment for myeloproliferative neoplasms (MPNs).
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
IMGO
Country
🇺🇸 United States